Kerusso Capital Management LLC Acquires New Stake in Pfizer Inc. (NYSE:PFE)

Kerusso Capital Management LLC bought a new position in Pfizer Inc. (NYSE:PFE) during the second quarter, HoldingsChannel.com reports. The fund bought 104,322 shares of the biopharmaceutical company’s stock, valued at approximately $2,919,000. Pfizer accounts for 2.1% of Kerusso Capital Management LLC’s portfolio, making the stock its 17th biggest position.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Gilbert & Cook Inc. increased its position in shares of Pfizer by 3.8% during the fourth quarter. Gilbert & Cook Inc. now owns 25,651 shares of the biopharmaceutical company’s stock worth $738,000 after acquiring an additional 945 shares during the period. Gryphon Financial Partners LLC grew its stake in Pfizer by 43.7% in the fourth quarter. Gryphon Financial Partners LLC now owns 26,942 shares of the biopharmaceutical company’s stock worth $861,000 after purchasing an additional 8,194 shares in the last quarter. AGF Management Ltd. increased its holdings in Pfizer by 377.2% during the 4th quarter. AGF Management Ltd. now owns 1,001,251 shares of the biopharmaceutical company’s stock worth $28,826,000 after purchasing an additional 791,452 shares during the period. Qsemble Capital Management LP bought a new stake in Pfizer during the 4th quarter valued at $1,200,000. Finally, Jump Financial LLC lifted its holdings in shares of Pfizer by 1,903.1% in the 4th quarter. Jump Financial LLC now owns 155,921 shares of the biopharmaceutical company’s stock worth $4,489,000 after buying an additional 148,137 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. UBS Group increased their price objective on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Wells Fargo & Company lifted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Finally, Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Eight analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Trading Up 0.2 %

Shares of NYSE:PFE opened at $28.56 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The firm has a market capitalization of $161.84 billion, a P/E ratio of -476.00, a P/E/G ratio of 1.02 and a beta of 0.68. The business’s 50-day moving average is $29.06 and its 200 day moving average is $28.05. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $34.64.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.46 by $0.14. The firm had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. Pfizer’s revenue was up 2.1% on a year-over-year basis. During the same period last year, the firm posted $0.67 EPS. On average, research analysts predict that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th were issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.88%. The ex-dividend date was Friday, July 26th. Pfizer’s dividend payout ratio (DPR) is presently -2,800.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.